Form 4: Director Jack Kaye Reports uniQure Equity Transactions

Director Jack Kaye acquired restricted share units and stock options while selling shares to cover tax obligations.

Summary

• Director Jack Kaye received a grant of 7,550 restricted share units (RSUs) on June 10, 2026.
• Director Jack Kaye was granted 13,980 stock options with an exercise price of $26.82 on June 10, 2026.
• A total of 1,993 shares were sold on June 11, 2026, at a weighted average price of $27.06 to satisfy tax withholding obligations.
• Following these transactions, the director holds 25,996 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine director compensation and tax compliance.

Positives

• Director maintains a significant equity stake in the company.
• Equity grants align director interests with long-term shareholder value.

Negatives

• The sale of 1,993 shares, while non-discretionary, reduces the total direct share count.

Risks

• Vesting of RSUs and options is contingent upon the director's continued relationship with the issuer.

Future Outlook

The RSUs and stock options vest 100% on the first anniversary of the grant date, June 10, 2027, subject to continued service.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance and executive compensation practices within the biotechnology sector, where equity-based incentives are common for retaining board members.

Comparison to Industry Standards

• The use of automatic sell-to-cover transactions for tax obligations is a standard practice for corporate insiders in the U.S. equity markets.
• The one-year cliff vesting schedule for director equity is consistent with typical biotech industry compensation structures.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were primarily related to compensation and tax obligations.

Next Steps

• Vesting of restricted share units on June 10, 2027.
• Vesting of stock options on June 10, 2027.

Key Dates

Keywords

uniQure, QURE, Form 4, Insider Trading, Biotech, Equity Compensation